权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Weill Cornell/Rockefeller/Sloan Kettering MST Program

威尔康奈尔/洛克菲勒/斯隆凯特琳 MST 计划

基本信息

批准号：
10630118
负责人：
KATHARINE C HSU
金额：
$ 283.79万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1979
资助国家：
美国
起止时间：
1979-07-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10630118
关键词：
programs

项目摘要

PROJECT SUMMARY The Tri-Institutional MD-PhD Program is a joint undertaking of Weill Cornell Medicine (WCM), The Rockefeller University (RU), and the Sloan Kettering Institute for Cancer Research (SKI). Its mission is to train biomedical investigators who: on the one hand, have advanced understanding of biomedical science and a mastery of contemporary research skills, which will allow them to undertake fundamental studies to elucidate basic biological processes pertaining to human disease; and, on the other hand, are well grounded in human biology, pathobiology and clinical medicine, which will equip them to transfer advances in basic research to the understanding, prevention, and treatment of human disease. The three institutions operate three graduate schools: Weill Cornell Graduate School of Medical Sciences (WCGS), a joint undertaking between WCM and SKI; the David Rockefeller Graduate School at RU; and the Gerstner Graduate School of Biomedical Sciences (GSK) at SKI. The Tri-Institutional MD-PhD Program was formed in 1991, when two independent MD-PhD Programs, the WCM-RU Program and the WCM-WCGS Program, were joined to form the present program. GSK became part of the Program in 2009. MSTP trainees complete all requirements for the MD degree at WCM. They receive their PhD training in research laboratories in the three research institutions and receive their PhD degree from GSK, RU or WCGS. Accepted trainees arrive in early July before the start of medical school. During the first two years in the Program they complete their medical school course, take two graduate level courses designed for MD-PhD students, and complete three research rotations (in three different laboratories) before they settle into their thesis laboratory. When the students choose a research laboratory they enroll in the graduate school with which their thesis mentor is associated. The graduate course and thesis requirements are comparable for all MD-PhD students, irrespective of the graduate school in which they are matriculated—and the students can cross register and take courses for credit in any of the graduate schools. At the end of their research training, after they have defended their thesis, the students return to complete their clinical training at WMC. The present application requests funds to continue MD-PhD training at the three institutions beyond Year 45 (the predecessor WCMC-RU Program was formed in 1972; it received NIH funding in 1974). In its current iteration, the Program brings together faculty in more than 250 independent research laboratories. 379 MD- PhDs have graduated from the Tri-Institutional MD-PhD Program and its predecessors; currently there are 137 students in the Program. The current trainees come from 55 undergraduate schools. Their average GPA is 3.75. 94% of the graduates pursue post-graduate clinical training; of the 305 graduates who have completed their training, 258 (85%) have appointments in medical schools, research institutes or biotech/pharma.

项目摘要三机构MD-PhD计划是威尔康奈尔医学（WCM），洛克菲勒 Sloan Kettering癌症研究所（SKI）。它的使命是培养生物医学研究人员：一方面，对生物医学科学有深入的了解，当代研究技能，这将使他们能够进行基础研究，以阐明基本的与人类疾病有关的生物过程;另一方面，在人类生物学中有很好的基础，病理生物学和临床医学，这将使他们能够将基础研究的进展转移到了解、预防和治疗人类疾病。这三个机构经营三个研究生院：威尔康奈尔大学医学科学研究生院（WCGS），WCM和SKI之间的联合企业; RU的大卫洛克菲勒研究生院;以及格斯特纳生物医学科学研究生院（GSK）。三机构MD-PhD计划是成立于1991年，当时两个独立的MD-PhD计划，WCM-RU计划和WCM-WCGS 计划，被加入形成本计划。GSK于2009年成为该计划的一部分。 MSTP学员在WCM完成MD学位的所有要求。他们接受博士培训，在这三个研究机构的研究实验室，并获得博士学位GSK，RU或WCGS。接受的学员在医学院开学前的7月初到达。在最初的两年里，计划他们完成他们的医学院课程，采取两个研究生水平的课程设计的MD-PhD 学生，并完成三个研究轮换（在三个不同的实验室），然后才安顿下来，实验室论文当学生选择一个研究实验室，他们在研究生院注册，与他们的论文导师有关研究生课程和论文的要求是可比的所有 MD-PhD学生，无论他们被录取的研究生院-学生可以在任何一所研究生院交叉注册并修读课程以获得学分。在他们的研究训练结束时，完成论文答辩后，学生们返回WMC完成临床培训。本申请要求提供资金，以便在国际年之后继续在这三个机构进行医学博士-博士培训。 45（前身WCMC-RU计划成立于1972年; 1974年获得NIH资助）。以目前的迭代，该计划汇集了教师在250多个独立的研究实验室。379 MD- 博士毕业于三机构MD-PhD计划及其前身;目前有137个方案中的学生。目前的学员来自55所本科院校。平均GPA是 3.75. 94%的毕业生追求研究生临床培训; 305毕业生谁完成了 258人（85%）在医学院、研究机构或生物技术/制药公司任职。

项目成果

期刊论文数量（139）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

First-generation physician-scientists are under-represented and need better support.

DOI：
10.1038/s41591-021-01352-3
发表时间：
2021-05
期刊：
Nature medicine
影响因子：
82.9
作者：
Christophers B;Macedo B;Nieblas-Bedolla E;Marr M;Andersen OS;Boothroyd C
通讯作者：
Boothroyd C

Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk.

DOI：
10.3389/fgene.2014.00029
发表时间：
2014
期刊：
Frontiers in genetics
影响因子：
3.7
作者：
Willis JA;Mukherjee S;Orlow I;Viale A;Offit K;Kurtz RC;Olson SH;Klein RJ
通讯作者：
Klein RJ

Computational Approaches to Understanding the Role of Fibroblast-Myocyte Interactions in Cardiac Arrhythmogenesis.

DOI：
10.1155/2015/465714
发表时间：
2015
期刊：
BioMed research international
影响因子：
0
作者：
Brown TR;Krogh-Madsen T;Christini DJ
通讯作者：
Christini DJ

Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease.

DOI：
10.1371/journal.pone.0076359
发表时间：
2013
期刊：
PloS one
影响因子：
3.7
作者：
Rumah KR;Linden J;Fischetti VA;Vartanian T
通讯作者：
Vartanian T

The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin.

DOI：
10.1371/journal.ppat.1004896
发表时间：
2015-05
期刊：
PLoS pathogens
影响因子：
6.7
作者：
Rumah KR;Ma Y;Linden JR;Oo ML;Anrather J;Schaeren-Wiemers N;Alonso MA;Fischetti VA;McClain MS;Vartanian T
通讯作者：
Vartanian T